Besponsa ‘More Effective’ at Driving Remission for Pediatric B-ALL

OPACC
Apr 24, 2024
1 min read

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with relapsed or refractory B-ALL.

Comments

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

NCCN Guidelines Now Recommend Naxitamab for High-Risk Neuroblastoma

Common appliance raises kids’ cancer risk nearly twice as much as adults’

How protein-slayer drugs could beat some of the cruellest cancers

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

Pediatric Brain Tumor Risk Increases With CT Radiation Exposure

AI Predicts Pediatric Brain Tumor Relapse With Surprising Accuracy

Study identifies how malaria can lead to childhood cancer

'Phenomenal' - study hailed a significant milestone in child cancer care

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors

Recent Posts

Besponsa ‘More Effective’ at Driving Remission for Pediatric B-ALL

Comments

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

NCCN Guidelines Now Recommend Naxitamab for High-Risk Neuroblastoma

Common appliance raises kids’ cancer risk nearly twice as much as adults’

How protein-slayer drugs could beat some of the cruellest cancers

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

Pediatric Brain Tumor Risk Increases With CT Radiation Exposure

AI Predicts Pediatric Brain Tumor Relapse With Surprising Accuracy

Study identifies how malaria can lead to childhood cancer

'Phenomenal' - study hailed a significant milestone in child cancer care

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors

Archive

Search By Tags